Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Net Income towards Common Stockholders: 2016-2024

Historic Net Income towards Common Stockholders for Crinetics Pharmaceuticals (CRNX) over the last 9 years, with Dec 2024 value amounting to -$297.4 million.

  • Crinetics Pharmaceuticals' Net Income towards Common Stockholders fell 69.33% to -$130.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$422.7 million, marking a year-over-year decrease of 54.83%. This contributed to the annual value of -$297.4 million for FY2024, which is 42.19% down from last year.
  • Crinetics Pharmaceuticals' Net Income towards Common Stockholders amounted to -$297.4 million in FY2024, which was down 42.19% from -$209.2 million recorded in FY2023.
  • In the past 5 years, Crinetics Pharmaceuticals' Net Income towards Common Stockholders ranged from a high of -$74.0 million in FY2020 and a low of -$297.4 million during FY2024.
  • Moreover, its 3-year median value for Net Income towards Common Stockholders was -$209.2 million (2023), whereas its average is -$223.4 million.
  • Data for Crinetics Pharmaceuticals' Net Income towards Common Stockholders shows a maximum YoY slumped of 52.09% (in 2022) over the last 5 years.
  • Crinetics Pharmaceuticals' Net Income towards Common Stockholders (Yearly) stood at -$74.0 million in 2020, then plummeted by 45.41% to -$107.5 million in 2021, then crashed by 52.09% to -$163.6 million in 2022, then fell by 27.88% to -$209.2 million in 2023, then slumped by 42.19% to -$297.4 million in 2024.